Last reviewed · How we verify
Rasburicase (SR29142)
Rasburicase (SR29142) is a Recombinant urate oxidase Small molecule drug developed by Sanofi. It is currently FDA-approved for Tumor lysis syndrome prevention and treatment in patients with hematologic malignancies at high risk of rapid cell turnover, Hyperuricemia management in patients receiving chemotherapy.
Rasburicase is a recombinant urate oxidase enzyme that catalyzes the conversion of uric acid to allantoin, a more soluble metabolite that is readily excreted.
Rasburicase is an enzyme used to treat conditions such as Leukemia, Lymphoma, Tumor Lysis Syndrome, Hyperuricemia, and Gout. It works by breaking down uric acid through its action as a uric acid oxidative enzyme.
At a glance
| Generic name | Rasburicase (SR29142) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Recombinant urate oxidase |
| Target | Uric acid (substrate); urate oxidase enzyme |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Rasburicase breaks down uric acid into allantoin, which is approximately 5–10 times more soluble than uric acid in urine. This prevents uric acid crystal formation and reduces serum uric acid levels rapidly, thereby preventing or treating tumor lysis syndrome and associated complications such as acute kidney injury and hyperuricemia.
Approved indications
- Tumor lysis syndrome prevention and treatment in patients with hematologic malignancies at high risk of rapid cell turnover
- Hyperuricemia management in patients receiving chemotherapy
Common side effects
- Allergic reactions (including anaphylaxis)
- Hemolysis (particularly in G6PD-deficient patients)
- Methemoglobinemia
- Fever
- Nausea and vomiting
Key clinical trials
- Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients (PHASE2)
- Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome (PHASE4)
- Mature B-Cell Lymphoma And Leukemia Study III (PHASE2, PHASE3)
- Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease (PHASE2)
- An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201) (PHASE2)
- Rasburicase Treatment in Chronic Gouty Arthritis (PHASE4)
- Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma (PHASE3)
- Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rasburicase (SR29142) CI brief — competitive landscape report
- Rasburicase (SR29142) updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Rasburicase (SR29142)
What is Rasburicase (SR29142)?
How does Rasburicase (SR29142) work?
What is Rasburicase (SR29142) used for?
Who makes Rasburicase (SR29142)?
What drug class is Rasburicase (SR29142) in?
What development phase is Rasburicase (SR29142) in?
What are the side effects of Rasburicase (SR29142)?
What does Rasburicase (SR29142) target?
Related
- Drug class: All Recombinant urate oxidase drugs
- Target: All drugs targeting Uric acid (substrate); urate oxidase enzyme
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Tumor lysis syndrome prevention and treatment in patients with hematologic malignancies at high risk of rapid cell turnover
- Indication: Drugs for Hyperuricemia management in patients receiving chemotherapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing